

## 2023 Agenda

### 3rd Annual MDA Insights in Research Investor Summit (IRIS) for Neuromuscular Disease

\*All times listed are Central Daylight Time (CT)

Tuesday, March 21, 2023 (MORNING)	
9:00 a.m. — 9:10 a.m.	<b>Opening Remarks</b>
<b>ALS Focused Opportunities</b>	
9:10 a.m. — 9:30 a.m.	<b>Advanced predictive analytics for late phase clinical development drug rescue</b>   David L. Ennist, PhD, MBA — Origent Data Sciences
9:30 a.m. — 9:50 a.m.	<b>Novel non-invasive approach to ALS treatment using neuronal hyperexcitability suppression</b>   Nader Yaghoubi, MD, PhD — PathMaker Neurosystems
9:50 a.m. — 10:10 a.m.	<b>Novel Small Molecules with Neuroprotective Potential in ALS and Related Neurodegenerative Disorders</b>   Daniela Zarnescu — Penn State College of Medicine
<b>Muscular Dystrophy Focused Opportunities</b>	
10:10 a.m. — 10:30 a.m.	<b>Constant Therapeutics: Targeting the Alternative Renin Angiotensin System</b>   Rick Franklin, MD, PhD — Constant Therapeutics LLC
10:30 a.m. — 11:00 a.m.	<b>Break</b>
11:00 a.m. — 11:20 a.m.	<b>Therapeutic Targeting of a Pathological MicroRNA in Duchenne and Becker Muscular Dystrophy</b>   Anders M. Naar, PhD — Elenae Therapeutics Inc.
11:20 a.m. — 11:40 a.m.	<b>Development and Phase I/II Clinical Trial of MyoPAXon, a Cell Therapy Platform for Muscle Regeneration</b>   Al Hawkins — Myogenica
11:40 a.m. — 12:00 p.m.	<b>Therapeutic Restoration of Muscle Regeneration in Duchenne</b>   Ryan Mitchell, PhD — Satellos Biosciences Inc.
12:00 p.m. — 1:30 p.m.	<b>Lunch</b>
1:30 p.m. — 2:30 p.m.	<b>Panel Discussion – Changing Landscape of Funding and Commercializing Innovative Therapies</b>   Chair: Michael Rice, PhD — Lumanity Inc., Panelists: Chris Garabedian, Xontogeny; Lianna Orlando, CureDuchenne; and Leslie Williams, hC Bioscience Inc.

**2023 Agenda Continued...**

Tuesday, March 21, 2023 (AFTERNOON)	
Muscular Dystrophy Focused Opportunities Continued	
2:30 p.m. — 2:50 p.m.	<b>Sarcomatrix, Inc. Advancing Novel Oral <math>\alpha</math>7 Integrins and Protein Replacement Therapies with the Potential to Treat Patients Afflicted with DMD, BMD, CMD and Possibly Other Muscular Dystrophies</b>   David Craig, RPh, MBA — Sarcomatrix, Inc.
2:50 p.m. — 3:10 p.m.	<b>Small Molecule Multi-Parametric Rescue of an Animal Model of Duchenne muscular Dystrophy</b>   Christine Charman, Ph.D. — MitoRx Therapeutics Limited
3:10 p.m. — 3:30 p.m.	<b>Mantarray Platform: Democratizing Human 3D Muscle Tissues for Neuromuscular Disease Impact</b>   Greg Luerman, Ph.D. — Curi Bio
Other NMD Focused Opportunities	
3:30 p.m. — 3:50 p.m.	<b>Gene Therapy to Regenerate the Neuromuscular Junction</b>   Patricio Sepulvedac, Ph.D., MBA — Amplo Biotechnology